Relevant bibliographies by topics / Activated partial thromboplastin time

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Activated partial thromboplastin time'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Activated partial thromboplastin time.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Activated partial thromboplastin time"

1

Ciavarella, N., S. Coccheri, P. M. Mannucci, M. Teresa Canciani, G. Mariani, P. G. Mori, Maria Orlando, L. Tentori, and O. Ponari. "Activated Partial Thromboplastin Time." Scandinavian Journal of Haematology 25, no. 4 (April 24, 2009): 308–17. http://dx.doi.org/10.1111/j.1600-0609.1981.tb01408.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

BASHEVKIN, MICHAEL L. "The Activated Partial Thromboplastin Time." Annals of Internal Medicine 105, no. 3 (September 1, 1986): 470. http://dx.doi.org/10.7326/0003-4819-105-3-470_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

FRANCIS, ROBERT B. "The Activated Partial Thromboplastin Time." Annals of Internal Medicine 105, no. 4 (October 1, 1986): 626. http://dx.doi.org/10.7326/0003-4819-105-4-626_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spinler, Sarah A. "Activated Partial Thromboplastin Time Evaluation." Pharmacotherapy 21, no. 3 (March 2001): 363–64. http://dx.doi.org/10.1592/phco.21.3.363.34203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ames, Paul R. J., Maria Graf, Jeremy Archer, Nicola Scarpato, and Luigi Iannaccone. "Prolonged Activated Partial Thromboplastin Time." Clinical and Applied Thrombosis/Hemostasis 21, no. 2 (July 2, 2014): 149–54. http://dx.doi.org/10.1177/1076029614541516.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Esmedere Eren, Sevim, Cigdem Karakukcu, Mehmet Z. Ciraci, Yasemin Ustundag, and Musa Karakukcu. "Activated partial thromboplastin time derivative curves." Blood Coagulation & Fibrinolysis 29, no. 4 (June 2018): 410–14. http://dx.doi.org/10.1097/mbc.0000000000000728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Low, C. L., G. Eisele, and G. R. Bailie. "Correlation of whole blood activated partial thromboplastin time and plasma activated partial thromboplastin time in haemodialysis patients." Nephrology Dialysis Transplantation 11, no. 12 (December 1, 1996): 2523. http://dx.doi.org/10.1093/oxfordjournals.ndt.a027236.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Smythe, Maureen A., John M. Koerber, Sandra N. Nowak, Joan C. Mattson, Robert L. Begle, Susan J. Westley, and Mamtha Balasubramaniam. "Correlation between Activated Clotting Time and Activated Partial Thromboplastin Times." Annals of Pharmacotherapy 36, no. 1 (January 2002): 7–11. http://dx.doi.org/10.1345/aph.1a141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kuss, Erich. "Use of the Activated Partial Thromboplastin Time." Annals of Internal Medicine 109, no. 4 (August 15, 1988): 347. http://dx.doi.org/10.7326/0003-4819-109-4-347_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pedersen, Joseph T., Matthew R. Pincus, and Judith A. Rapiejko. "Comparison of Activated Partial Thromboplastin Time Reagents." Laboratory Medicine 19, no. 7 (July 1, 1988): 421–24. http://dx.doi.org/10.1093/labmed/19.7.421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Activated partial thromboplastin time"

1

Hobby, Deanna Jeanne. "A COMPARISON OF ACTIVATED PARTIAL THROMBOPLASTIN TIME OBTAINED BY TWO TECHNIQUES IN PATIENTS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY." Thesis, The University of Arizona, 1987. http://hdl.handle.net/10150/291339.

Full text
Abstract:
A descriptive study was conducted to test the null hypothesis: There will be no statistically significant difference between serum activated partial thromboplastin time (aPTT) obtained by two methods; venipuncture and large bore femoral arterial catheter. The convenience sample consisted of seventeen adults who had undergone percutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronary artery disease. After the PTCA procedure, patients returned to an intensive care unit with a femoral intra-arterial catheter in place. Seventeen pairs of serum samples were obtained; one by venipuncture and one through the femoral intra-arterial catheter. Prior to obtaining the sample from the femoral intra-arterial catheter, 6.0 milliliters (3 times the deadspace of the catheter) of blood was withdrawn and discarded. aPTT samples were analyzed. T-tests were used to compare the results. Findings revealed that there was no statistically significant difference in the aPTT value when drawn from venipuncture versus the femoral intra-arterial catheter.
APA, Harvard, Vancouver, ISO, and other styles
2

Sousa, Ivancia Donato de Luna. "Estudos hemostáticos secundários causados pela peçonha bruta, frações proteicas e proteínas isoladas da peçonha de Crotalus durissus terrificus." Universidade Federal da Paraíba, 2017. http://tede.biblioteca.ufpb.br:8080/handle/tede/9414.

Full text
Abstract:
Submitted by Vasti Diniz (vastijpa@hotmail.com) on 2017-09-05T11:37:07Z No. of bitstreams: 1 arquivototal.pdf: 12321568 bytes, checksum: e2f13c138059f4c0542b89fde505f812 (MD5)
Made available in DSpace on 2017-09-05T11:37:07Z (GMT). No. of bitstreams: 1 arquivototal.pdf: 12321568 bytes, checksum: e2f13c138059f4c0542b89fde505f812 (MD5) Previous issue date: 2017-03-29
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
Snakebites (Ophidism) are listed by the World Health Organization as a neglected tropical disease and are considered a public health problem. Among the activities triggered by envenoming from Crotalus durissus terrificus snake venom, the coagulant one is intriguing and contradictory, curious and contradictory, since the venom has, in its composition, coagulation precursor proteins and anticoagulant proteins. The present work describes, in vitro, the performance of crude venom, protein fractions and purified proteins of Crotalus durissus terrificus venom on the coagulation factors of human plasma secondary hemostasis. The coagulant and / or anticoagulant activity of crude venom, protein fractions and purified proteins were evaluated directly on human citrated plasma. Changes in Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) were measured with commercial kits. Clots formed in the presence of crude venom, protein fraction # 7 and Gyroxin displayed as a hyaline flexible mass and steady state. The evaluation of the clot formation time in the presence of the protein fractions # 1 to # 6 and isolated proteins (Crotoxin complex, Crotoxin A, Crotoxin B and Crotamine), after the commercial tests (PT and APTT), allowed to infer that these proteins interfere in all pathways of the coagulation cascade. Therefore, the Crotoxin A, Crotoxin B, Crotoxin and Crotamine proteins may act similarly to some anticoagulants direct inhibitors of thrombin, factor Xa and antithrombin III activator. Moreover, Crotoxin B can inhibits the formation of the prothrombinase complex by direct interaction with factor Xa. Consequently, the protein content from C. d. terrificus snake venom can act synergistically in coagulation and dysfunction and / or inhibition of natural anticoagulants unbalancing hemostasis.
Acidentes ofídicos (ofidismo) são listados, pela Organização Mundial de Saúde, como doença tropical negligenciada e são considerados um problema de saúde pública. Dentre as atividades desencadeadas pelo empeçonhamento por Crotalus durissus terrificus, a coagulante é curiosa e contraditória, pois a peçonha apresenta, em sua composição, proteínas precursoras da coagulação e proteínas anticoagulantes. O presente trabalho descreve, in vitro, a atuação da peçonha bruta, de frações proteicas e proteínas purificadas da peçonha de Crotalus durissus terrificus sobre os fatores de coagulação da hemostasia secundária do plasma humano. A atividade coagulante e/ou anticoagulante da peçonha bruta, frações proteicas e proteínas purificadas foram avaliadas diretamente sobre o plasma citratado humano e as alterações no Tempo de Protrombina (TP) e no Tempo de Tromboplastina Parcial Ativada (TTPA) foram aferidos com kits comerciais. Os coágulos formados na presença da peçonha bruta, da fração proteica #7 e da Giroxina apresentaram-se como uma massa hialina de textura flexível e pontual. A avaliação do tempo de formação dos coágulos na presença das frações proteicas #1 até #6 e das proteínas isoladas Crotoxina, Crotoxina A, Crotoxina B e Crotamina, após a aplicação dos testes comerciais (PT e APTT), possibilitou inferir que essas proteínas interferem em todas as vias da cascata de coagulação. Por conseguinte, as proteínas Crotoxina A, Crotoxina B, Crotoxina e Crotamina podem atuar de forma semelhante a alguns anticoagulantes inibidores direto de trombina, do fator Xa e do ativador da antitrombina III. Ainda, a Crotoxina B pode inibir a formação do complexo protrombinase por interação direta com o fator Xa. Consequentemente, o conteúdo proteico da peçonha de C. d. terrificus pode atuar de forma sinérgica na coagulação e na disfunção e/ou inibição dos anticoagulantes naturais desequilibrando a hemostasia.
APA, Harvard, Vancouver, ISO, and other styles
3

Cullberg, Marie. "Direct Thrombin Inhibitors in Treatment and Prevention of Venous Thromboembolism: Dose – Concentration – Response Relationships." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Universitetsbiblioteket [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6872.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moroz, Ludmila Rodrigues. "Avaliação de parâmetros hemostáticos em cães de diferentes categorias de risco anestésico no período peri-operatório." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/10/10137/tde-19012009-105846/.

Full text
Abstract:
A hemostasia é um evento biológico passível de ser avaliado e estudado, assim como seus distúrbios. Há situações durante a anestesia que podem cursar com alterações hemostáticas culminando com aumento do sangramento ou até mesmo hemorragias graves. Os tempos de coagulação têm recebido especial atenção tendo-se em vista os diferentes contratempos hemostáticos que pode ocorrer durante o procedimento anestésico-cirúrgico. Sendo assim, nesse estudo buscou-se estabelecer os valores padrões para tempo de protrombina (TP) e de tromboplastina parcial ativada (TTPA) para cães submetidos a diferentes procedimentos cirúrgicos. Foram estudados 50 cães hígidos para padronização dos valores de TTPA e TP utilizando aparelho automático. Os valores de TTPA estavam dentro dos valores de normalidade da literatura (6,9 a 17,6 segundos) e valores de TP discretamente maiores (de 6,65 a 12,8 segundos). Foram estudadas 20 cadelas classificadas como ASA I e 18 cães ASA II e III. Nestes animais observaram-se aumentos significativos de valores de TTPA (de 12,04 para 14,29 segundos em ASA I, com P<0,0378; e de 13,4 para 15,11 segundos nos cães ASA II e III, P<0,0067) e de TP (de 8,36 para 9,7 segundos em ASA I, P<0,0323; e de 8,32 para 9,34 segundos nos caes ASA II e III, P< 0,0084) entre os momentos pré e pós-anestésicos Estes aumentos acompanham quedas da pressão coloidosmótica, indicando que o processo de anestesia, cirurgia e fluidoterapia causam hemodiluição, e conseqüente aumento nos tempo de coagulação.
Hemostasis is a biological event that could be evaluated and studied, just like yours disturbs. There are situations in to anesthetic procedures that could curse with hemostatics disturbs causing bleeding increase or even critical blood loss. The blood clotting times have been received special attention because different hemostatic setbacks that could occur during the anesthetic and surgical procedures. This way, this study look for establish the values for reference to protrombine time (PT) and to activated partial tromboplastin time (APTT) for dogs. Were studied 50 healthy dogs to standardize the values of PT and APTT utilizing an automatic instrument. The APTT values was in agreement with the literature values (6,9 to 17, 6 seconds), and the PT values was discret increased when compared with literature (from 6,65 to 12,8 seconds). Was studied 20 bitches classifieds as ASA I and 18 dogs classifieds as ASA II and III. In this animals observed significant increase values of APTT (from 12,04 to 14,29 seconds in the ASA I, P<0,0378; and from 13,4 to 15,11 seconds in the dogs ASA II and III, P<0,0067) and of PT (from 8,36 to 9,7 seconds in ASA I, P<0,0323; and from 8,32 to 9,34 seconds in the ASA II and III dogs) between the pre and post anesthetic moments. These increases attendance decease in the colloid osmotic pressure, indicating that the anesthetic, surgical and fluid therapy procedures can cause hemodilution, and consequent increase in the blood clotting times.
APA, Harvard, Vancouver, ISO, and other styles
5

Nkunjana, Thobela. "The effect of homeopathically prepared Arnica Montana 6C on bleeding, prothrombin and activated partial thromboplastin times in Vivo." Thesis, 2012. http://hdl.handle.net/10210/6025.

Full text
Abstract:
M.Tech.
Haemostasis is an internal mechanism to stop bleeding from a damaged blood vessel. Conceptually this process occurs in a number of essential steps following tissue injury. Although the herbal preparation of Arnica montana has been well documented for its tendency to prolong bleeding, according to the Law of Similars, homeopathically prepared Arnica montana 6C is well indicated for traumatic injuries and post surgical bruising. Arnica montana 6C can be used when there is mechanical trauma that causes wounds, haemorrhages, haematomas, sore-bruised bone and muscular pains, inflammations, fractures, muscular strains and sprains. The remedy is often prescribed before and immediately after surgery to reduce post-operative pain and to speed up recuperation. Three in vitro studies conducted at the Technikon Witwatersrand (now the University of Johannesburg) on various potencies of homeopathically prepared Arnica montana showed lowered overall coagubility of blood, but no significant difference between the experimental and control groups. Bengsch (2000), Hohl (2005), Vermeulen (2000) and van Tonder (2005) recommended that studies on the effect of homeopathically prepared Arnica montana on blood coagulability be repeated in vivo. This study formed part of a three part in vivo study to determine the effect of Arnica montana homeopathic preparations on blood coagulation by measuring the Bleeding Time (BT), activated Partial Thromboplastin Time (aP'TT) and Prothrombin Time (PT). This study investigated the effect of Arnica montana 6C on these measurements. Eighty participants were allocated a participant number and randomised by the research supervisor into four groups of twenty participants. Twenty participants were in the placebo group that was shared by all three studies. Twenty participants were allocated to the experimental group for this study. The study was conducted over a period of two weeks at the University of Johannesburg (UJ) Doomfontein Campus Homeopathy Health Centre. Consenting participants were screened by means of a questionnaire (Appendix D) regarding relevant medical history and other background information. A case history was taken and a physical examination was performed. Any prospective participants that were diagnosed with and/or suffer from hypertension, hypotension, heart disease, a iii bleeding disorder, anaemia, iron or any vitamin deficiency, liver disease, malaria or are currently on aspirin or anticoagulants (Appendix D) were excluded from the study. The bleeding time was measured by a trained medical technologist using a standardised bleeding time technique. Blood samples drawn by a phlebotomist went for coagulation tests comprising of aPTT and PT at the NHLS Main Haematology laboratory of the Johannesburg Hospital. Twenty participants were given a 25mL bottle of Arnica montana 6C in 20% ethanol. Twenty participants received an identical bottle containing only 20% ethanol. All participants were requested to take ten drops twice a day for two weeks. All three coagulation test measurements were performed again at the end of the second week. The BT, PT and aPTT results were analysed by using ordinary descriptive statistics such as mean and standard deviation. Changes over time in blood coagulation were ascertained utilising ANOVA (analysis of variance). The results showed that there is no statistically significant difference between the experimental and control group in BT, aPTT and PT. There was also no statistically significant difference between the first BT, PT and aPTT before medication and the second BT, PT and aPTT after two weeks of medication. The results of the study support the hypothesis that Arnica montana 6C would have no effect on the bleeding or coagulation times in vivo. These results support the view that prescribing the remedy before surgery is not likely to increase the post surgical risk of haemorrhage
APA, Harvard, Vancouver, ISO, and other styles
6

Neaves, Alicia Louise. "An in vivo study of the effects of Arnica montana 30C on blood coagulation by measuring : prothrombin, activated partial thromboplastin and bleeding time." Thesis, 2014. http://hdl.handle.net/10210/11905.

Full text
Abstract:
M.Tech. (Homoeopathy)
Haemostasis is defined as the arrest of bleeding by formation of a haemostatic plug or clot. The herb Arnica montana interferes with this process thus resulting in increased bleeding. Homoeopathic physicians use Arnica montana in a potentised form for the treatment of post-operative swelling, pain and ecchymosis but little is known on what effect this potentised form of Arnica montana has on blood coagulation and bleeding time. This study forms part of a three part in vivo study to determine the effects of various homoeopathic potencies of Arnica montana on blood coagulation. This was done by measuring the Bleeding Time (BT), activated Partial Thromboplastin Time (aPTT) and the International Normalised Ratio (INR) of Prothrombin Time (PT). The aim of this particular study is to investigate the in vivo effect of Arnica montana 30C on blood coagulation and Bleeding Time. This study is a double blind, placebo controlled study that took place over a period of two weeks. A total sample group for the three part study consisted of eighty healthy participants between the ages of eighteen to thirty five. Consenting participants that met the criteria were randomised into four groups of twenty each. One group for each part of the three part study were the experimental group and one group was allocated to the placebo group that was shared by all three studies. BT was taken as well as blood samples which underwent coagulation tests (aPTT and INR). Twenty participants received Arnica montana 30C in 20% ethanol and twenty participants received an identical bottle containing 20% ethanol. After two weeks another blood sample was taken where all three coagulation test measurements were repeated. The results of the BT, INR and aPTT were analysed using Statkon Statistical Package for Social Sciences. This showed no statistical difference between the experimental or control group with regard to BT, INR and aPTT. The results indicate that Arnica montana 30C appears to have no effect on Bleeding Time..
APA, Harvard, Vancouver, ISO, and other styles
7

Hillmann, Nadine. "Methodenvergleich zur Erfassung einer Restheparinisierung nach kardiochirurgischen Eingriffen mit Herz-Lungen-Maschine." Doctoral thesis, 2016. http://hdl.handle.net/11858/00-1735-0000-002B-7CD3-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Activated partial thromboplastin time"

1

Stanworth, Simon, and Stuart McKechnie. Pathophysiology of disordered coagulation. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0269.

Full text
Abstract:
Imbalances in the regulation of haemostasis may manifest as bleeding (depletion of pro-coagulant factors) or thrombosis (deficiency of anti-coagulants). Disordered haemostasis is common in critically-ill patients and may result from infection, trauma, haemorrhage, inflammation, organ dysfunction (notably renal and liver dysfunction), or drug therapy. Complex patterns of coagulopathy where both bleeding and prothrombotic tendencies co-exist are well recognized in critical illness. The limitations of standard laboratory coagulation tests to predict bleeding risk, including activated partial thromboplastin time and prothrombin time, are well recognized. These assays were developed for diagnosis of inherited bleeding disorders or for monitoring of anticoagulant therapy. This has led to increased interest in global haemostatic tests, such as viscoelastic and thrombin generation tests. Thromboembolism is an important cause of morbidity and mortality in critically-ill patients. While inherited causes of bleeding appear to be often related to single gene abnormalities, thrombotic tendencies appear to reflect more complex interactions between inherited and acquired factors. Many interactions exist between coagulation pathways and inflammation. Systemic inflammation triggers widespread activation of coagulation, with pro-inflammatory cytokines activating pro-coagulant pathways and downregulating anticoagulant pathways. A net result of this interaction between inflammatory and coagulation pathways in sepsis is thrombin generation, intravascular fibrin deposition and a consumptive coagulopathy.
APA, Harvard, Vancouver, ISO, and other styles
2

Marchal, Joseph A. Appalling Bodies. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780190060312.001.0001.

Full text
Abstract:
The letters of Paul are among the most commonly cited biblical texts in ongoing cultural and religious disputes about gender, sexuality, and embodiment. This book reframes these uses of the letters by reaching past Paul toward other, far more fascinating figures that appear before, after, and within the letters: androgynous females, castrated males, enslaved people, and barbaric foreigners. Each of these ancient figures deployed in these letters is situated within a specifically Roman imperial setting, an ambiance that cast them as complicated, debased, and dangerous. While the letters repeat and reinscribe the prevailing perspectives on this constellation of embodied figures, this project repositions them by implementing key insights from queer studies. In juxtaposing them against more recent figures of gender and sexual variation, also subject to vilification and marginalization, this project provides a series of alternative angles on these figures and the assemblies who spark and receive these letters, then or now. In staging a series of “touches across time,” Appalling Bodies defamiliarizes and reorients what can be known about both the historical figures active in these ancient communities and those rhetorical figures that continue to be activated in contemporary settings. The aim is not to claim, anachronistically, that these figures are somehow identical to each other; rather, it is through anachronistic juxtaposition that the book highlights contingent connections—partial, particular, but shared practices of gender, sexuality, and embodiment that depart from prevailing perspectives and demonstrate a range of unexpected impacts for the interpretation of politically and religiously loaded literature.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Activated partial thromboplastin time"

1

Ignjatovic, Vera. "Activated Partial Thromboplastin Time." In Haemostasis, 111–20. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-339-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Poller, L. "Activated partial thromboplastin time (APTT)." In Laboratory Techniques in Thrombosis - a Manual, 37–44. Dordrecht: Springer Netherlands, 1999. http://dx.doi.org/10.1007/978-94-011-4722-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Poller, L., and J. M. Thomson. "The activated partial thromboplastin time (APTT)." In ECAT Assay Procedures A Manual of Laboratory Techniques, 35–40. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2992-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tripodi, Armando, and Veena Chantarangkul. "Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT)." In Methods in Molecular Biology, 177–83. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7196-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kershaw, Geoffrey. "Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants." In Methods in Molecular Biology, 75–83. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7196-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cotton, Bryan A., and Laura A. McElroy. "Partial Thromboplastin Time." In Encyclopedia of Trauma Care, 1157–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-29613-0_75.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goel, Ruchika, and Paul M. Ness. "Prothrombin and Partial Thromboplastin Time." In Trauma Induced Coagulopathy, 221–26. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28308-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Crowe, Elizabeth P., Ruchika Goel, and Paul M. Ness. "Prothrombin and Partial Thromboplastin Time." In Trauma Induced Coagulopathy, 265–70. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-53606-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Damodaran, Senthilkumar, and Spero R. Cataland. "Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time, and Platelet Count." In The Coagulation Consult, 87–97. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9560-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, G. X., Q. Zhang, Y. Shen, L. J. Wan, D. Y. Jia, C. J. Tang, S. P. Ge, and Q. S. Yu. "Investigation of Plasma Protein Adsorption, Platelets Adhesion and Partial Thromboplastin Time on Plasma SiCOH Nanocoating." In IFMBE Proceedings, 173–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03900-3_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Activated partial thromboplastin time"

1

Seveso, M. P., A. Macagni, S. Viganò D’Angelo, A. G. Dettori, P. A. Bonini, and A. D’Angelo. "ACTIVATED PARTIAL THROMBOPLASTIN TIME MONITORING OF HEPARIN THERAPY: COMPARISON OF INSTRUMENTS AND REAGENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644168.

Full text
Abstract:
It is current clinical practice to monitor heparin therapy by maintainig the activated partial thromboplastin time (APTT) at 1.5-2.5 × control normal pool. There is however controversy regarding the choice of reagents with respect to their heparin sensitivity. Choice of instrumentation is also known to affect the results. We have compared two automatic coagulometers, the ACL (Instrumentation Laboratory), a laser-nephelometric centrifugal analyzer and the KOAGULAB 40A (Ortho Diagnostics), an optical automatic coagulometer, with the tilt tube technique for the performance of APTT. Seven commercial reagents have been used for APTT replicate determinations in 30 normals, 30 liver disease patients and 30 patients on heparin therapy (20-40,000 IU daily). The overall observed imprecision (C. V.)was 1.8% for ACL, 3.0% for KOAGULAB 40A and 2.3% for tilt tube technique. The F test for the two-way interaction of ratios was statistically significant (p<0.001) for the large majority of reagent/ technique combinations in normals, liver disease and heparin treated patients. The percentage of patients adequately, inadequately and excessively heparinazed obtained with the two automatic instruments and with the tilt tube technique were not sig nificantly different when using the same reagent. However, major differences were observed when comparing the different reagents. For instance, inadequately heparinized patients were 90% according to one reagent (Cephotest, Nyegaard) as opposed to 17% according to another reagent (APTT, Instrumentation Laboratory). These results stress the need for a standardized APTT reagent to provide effective laboratory monitoring of heparin treatment. .
APA, Harvard, Vancouver, ISO, and other styles
2

Ramaswamy, B., Y. T. Yeh, and S. Y. Zheng. "Microfluidic device to perform impedometric detection of Activated Partial Thromboplastin Time of blood." In TRANSDUCERS 2011 - 2011 16th International Solid-State Sensors, Actuators and Microsystems Conference. IEEE, 2011. http://dx.doi.org/10.1109/transducers.2011.5969391.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jhajhria, Sunil, Krista A. Wahby, Haitham El-Haddad, and Ayman O. Soubani. "Prolongation Of Activated Partial Thromboplastin Time In Patients Treated With Intravenous Heparin During Therapeutic Hypothermia." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

de Amorim, Robson, Davi Solla, Manoel Teixeira, and Wellingson Paiva. "Incremental prognostic value of the activated partial thromboplastin time and creatinine in addition to the CRASH score in traumatic brain injury patients." In XXXII Congresso Brasileiro de Neurocirurgia. Thieme Revinter Publicações Ltda, 2018. http://dx.doi.org/10.1055/s-0038-1673047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Furmaniak-Kazmierczak, E., J. Jagielski, and T. Wilusz. "THE EFECT OF CMTI-I INHIBITOR ON HUMAN BLOOD CLOTTING SYSTEM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644327.

Full text
Abstract:
Polipeptyde inhibitors for different serine proteases have been isolated from a variety of plants. Among them there are the inhibitors from squash seeds of molecular weight about 3 300 /1/. The experiments were carried out to determine the effect of one of the squash inhibitors /CMTI-I/ on human blood clotting system. The 0.1 ml of inhibitor /O,8-100 ug/ was added to 0,1 ml of normal intact plasma and incubated 0,5, 15, 30 and 60 minutes at 37°C. It was found that partial tromboplastin time /PTT/ and activated partial thromboplastin time /APTT/ were prolonged. CMTI-I did not show a progressive mode of action upon prolonged time of incubation. There was no effect of CMTI-I on prothrombin time /PT/, thrombin time /TT/ and Stypven-cephalin time /ScT/. The influence of CMTI-I on APTT of factor-XII and factor-XI deficient plasmas as well as on a plasma without factor-XII and factor-XI /exhausted plasma/ was studied. The APTTs of the factor-XII and factor-XI deficient plasmas were prolonged while the APTT of the "exhausted plasma" was unchanged. The performed experiments shown that CMTI-I inhibitor blocks the clot-promoting activity of contact activated plasma. This inhibitory action is stronger in the case of factor XI than of factor XII.1. Wieczorek M., et al., 1985, Biochem. Biophys. Res. Commun. 126:646-652.
APA, Harvard, Vancouver, ISO, and other styles
6

Chrobák, L., V. Rozsíval, and V. Herout. "A HEP ARINE-LIKE ANTICOAGULANT IN A PATIENT WITH WEGENER’S GRANULOMATOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644342.

Full text
Abstract:
In a 23-year-old man with Wegener’s granulomatosis and mild bleeding coagulation studies revealed a significant prolongation of the coagulation time (CT) prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), failure of TT and aPTT to correct in a 1:1 mixture with pooled normal plasma (PNP), correction of the prolonged TT with toluidine blue and correction of TT and aPTT both in vitro and in vivo^protamine sulphate (P.S.).All other coagulation tests, i.e.,bleeding time, platelet count? fibrinogen level, euglobulme lysis time were within normal limits. The patient did not receive heparine. TT after administration of 5ml of protamine sulphate i.v. to the patient became normal - 18,2 s (19,7 s).In summary a patient with Wegener s granulomatosis associated with an endogenous heparine-like anticoagulant is reported. The anticoagulant could be corrected both in vitro and in vivo by protamine sulphate.
APA, Harvard, Vancouver, ISO, and other styles
7

TSUNEIZUMI, I., T. MEGURO, and K. YAMADA. "SUDAY ON A SUBSTANCE FUNCTIONALLY LIKE PROTEIN C IN PLASMA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644303.

Full text
Abstract:
The present report first deals with the isolation and characterization of a substance found to demonstrate protein C like activity(PCLA). When it was activated by thrombin, the PCLA substance prolonged the activated partial thromboplastin time(aPTT). The activated PCLA substance also hydrolyzed synthetic substrates such as S�2238, S�2366 and S�2266,while the PCLA substance was not cross reacted with anti-protein C serum(Behring Manheim). The PCLA substance was adsorbed by both aluminium hydroxide gel and barium sulfate. The level of Km, optimum pH and optimum I.S. in the amido-lytic reaction with synthetic substrate is shown in the table.In the chromatography of Sepharose CL-6B gel, the PCLA substance was eluted in the fraction of higher molecular weight, while protein C was eluted with a lower fraction.This prompts an estimate that the molecular weight of the PCLA substance is approximately 200,000. Through DEAE-Sepharose CL-6B gel ion exchange chromatography, the PCLA substance was eluted by a lower ionic strength than was protein C.The levels of a PCLA substance were low in the patients with a vitamin K deficiency and in newborn infants. It is expected that our findings regarding the PCLA substance will be as clinically significant as that which we know about protein C at present.
APA, Harvard, Vancouver, ISO, and other styles
8

Hariman, H., J. R. Hughes, P. J. Grant, and J. A. Davies. "THE EFFECTS OF PHYSIOLOGICAL CONCENTRATIONS OF VASOPRESSIN ON COMPONENTS OF THE FIBRINOLYTIC PATHWAY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643121.

Full text
Abstract:
Evidence from studies in man suggests that vasopressin (aVP) at physiological concentrations activates the coagulation pathway, increases plasminogen activator activity and may have a role in the regulation of haemostasis under conditions of physical stress. Infusion of aVP in normal subjects increases plasma factor VIII concentrations and shortens the euglobulin clot lysis time (ECLT), but the mechanisms involved in these changes and their haemostatic significance are unclear. The aims of this study were to investigate the effects of aVP on the fibrinolytic pathway and to evaluate whether thrombin or plasmin are generated in vivo by aVP. After 30 min 0.9% saline infusion, vasopressin (20iu in 250ml 0.9% saline) was infused at 2.0 u/h for 1h in 9 normal subjects to achieve plasma aVP concentrations comparable to those attained during stress. Venous blood samples were taken before saline infusion (time 0) and every 30 min for 2h for assay of aVP, activated partial thromboplastin time (APTT), fibrinopeptide A (FPA), FPA generation time, FPBB15-42 ECLT, tissue-type plasminogen activator (t-PA) and t-PA inhibition. Plasma aVP rose frcm 0.5 pg/ml at time 0 to (median) 70.7 pg/ml at 90 min. The APTT shortened from 43.8 ± 1.9 to 34.4 ± 1.6 (SEM) seconds (p < 0.001) at 90 min. Plasma FPA and the FPA generation time remained unchanged (p > 0.05). Plasminogen activator activity rose from 36.4 ± 15.2 to 587.5 ± 206.6 units (p < 0.005), t-PA increased frcm 229.8 ± 20.4 to 1107.4 ± 224.1 ml.U/ml (p < 0.005) and t-PA inhibition fell frcm 7.9 ± 1.1 to 3.9 ± 0.9 I.U/ml (p < 0.05) in response to the aVP infusion. FPB815-42 increased frcm a baseline value of 1.7 ± 0.4 to 2.2 ± 0.7 pmol/ml after 90 min (p < 0.05). The results suggest the effects of aVP on fibrinolysis are due to an increase in t-PA and decrease in t-PA inhibition. The increase in FPBB 15-42 with no change in FPA supports the hypothesis that plasmin was generated by non-fibrin dependent pathways.
APA, Harvard, Vancouver, ISO, and other styles
9

Takamatsu, J., H. Saito, T. Kamiya, Y. Muranaka, Y. F. Minami, and H. T. Fan. "A NEW MUCOPOLYSACCHARIDE FROM STICHPUS JAPONICUS(SEA CUCUMBER) AND ITS ANTICOAGULANT PRORETIES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644185.

Full text
Abstract:
A new mucopolysaccharide(FGAG) has been isolated from the cell wall of Stichopus japonicua. The molecular weight of FGAG is about 50,000. The component sugar of the FGAG are identified as galactosamine, glucuronic acid, fucose and sulfate with the molar ratioof 1:0.94:0.84:3.60,respectively. The anticoagulant effects of FGAG were studied. At low concentration(lμg/ml), FGAG completely inhibited the rabbit plateletaggregation induced by thrombin and prolonged thrombin time of not only human plasma but purified fibrinogen solution to a similar extent, suggesting that action of FGAG is not depend on plasma component(antithrombin III and/or Heparin c.ofactor II).After intravenous injection into rabbits(lmg/kg),significant prolongation of activated partial thromboplastin time(APTT) was observed. Although the in vivo antithrombin activity of the FGAG was weaker than that of heparin.it lasted longer than that of heparin and was not inhibited by platelet factor 4.These results suggested that FGAG is a new and unique mucopolysaccharide with antithrombin activity and may come into use for the treatment ofDiseminated Intravascular Coagulation.
APA, Harvard, Vancouver, ISO, and other styles
10

Ehrlich, H. J., N. U. Bang, N. L. Esmon, and C. T. Esmon. "IN VIVO BEHAVIOR OF DETERGENT SOLUBILIZED PURIFIED RABBIT THROMBOMODULIN INJECTED INTO RABBITS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643966.

Full text
Abstract:
Thrombomodulin (TM) is a thrombin (T) endothelial cell membrane receptor; the TM-T complex readily activates protein C resulting in anticoagulant activity. We investigated the biological effects of detergent solubilized purified rabbit TM upon i.v. injection into rabbits. 125I-labelled TM (lactoperoxidase method) disappeared from the circulation to a t 1/2 of 2.5 h.The administration to rabbits of 2 doses of 50 μg/kg endotoxin 24 h apart did not accelerate the turnover rate of TM. In vitro tests demonstrated that .27 nM TM was required to significantly prolong the activated partial thromboplastin time (APTT) and .54 nM to significantly prolong the thrombin clotting time (TCT). At 3.78 nM TM, both the APTT and TCT prolonged to infinity while the prothrombin time (PT) was minimally affected. When TM was injected into rabbits in doses of 100, 200 and 500 μg/ml APTT and TCT immediately prolonged in a dose dependent fashion whereas no effect on the PT was observed. The disappearance rate of anticoagulant activity (prolongation of the APTT and TCT) closely paralleled the disappearance rate of 125I-labelled TM; t 1/2 for anticoagulant activity being 2.0 h irrespective of the dose administered. Thus, detergent solubilized purified rabbit TM survives in the circulation for appreciable time periods. While in the circulation TM is capable of binding T thereby prolonging the TCT as well as activating protein C thereby causing degradation of factors Va and VIIIa resulting in a prolongation of the APTT. Therefore, TM administered i.v. results in an anticoagulant effect of surprisingly long duration.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Activated partial thromboplastin time' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography